gives off heat of less than 1 2 joules per gram for the particles having a mean particle size of less than 10 u03bcm as described and measured in u s pat no 5 874 063 the invention therefore provides a pharmaceutical formulation in the solid state comprising in admixture a first active ingredient which is micronised formoterol or an enantiomer thereof a second active ingredient which is a micronised glucocorticosteroid and a carrier diluent and having a high storage stability characterised in that the formulation is prepared by micronisation of the first active ingredient and carrier diluent optionally followed by mixing pre micronised coarser carrier diluent mixing with micronised hydrophobic second active ingredient and finally either subjecting the mixture to agglomeration and spheronisation or adding coarse carrier diluent the formoterol can be in the form of a mixture of enantiomers preferably the formoterol is in the form of a single enantiomer preferably the r r enantiomer the formoterol can be in the form of the free base salt or solvate or a solvate of a salt preferably the formoterol is in the form of its fumarate dihydrate salt other suitable physiologically salts include chloride bromide sulphate phosphate maleate tartrate citrate benzoate 4 methoxybenzoate 2 or 4 hydroxybenzoate 4 chlorobenzoate p toluenesulphonate benzenesulphonate ascorbate acetate succinate lactate glutarate gluconate tricaballate hydroxynapaphthalenecarboxylate or oleate preferably the second active ingredient is a micronised glucocorticosteroid such as budesonide fluticasone propionate mometasone furoate ciclesonide and epimers esters salts and solvates of these compounds more preferably the second active ingredient is budesonide or an epimer thereof most preferably the 22r epimer of budesonide preferably the carrier is a carbohydrate having a high storage stability preferably a reducing carbohydrate such as lactose glucose galactose mannose xylose maltose cellobiose mellibiose maltotriose e g as monohydrate.